DK2739153T3 - TREATMENT OF BREAST CANCER - Google Patents

TREATMENT OF BREAST CANCER Download PDF

Info

Publication number
DK2739153T3
DK2739153T3 DK12846720.6T DK12846720T DK2739153T3 DK 2739153 T3 DK2739153 T3 DK 2739153T3 DK 12846720 T DK12846720 T DK 12846720T DK 2739153 T3 DK2739153 T3 DK 2739153T3
Authority
DK
Denmark
Prior art keywords
compound
breast cancer
cells
inhibitors
dht
Prior art date
Application number
DK12846720.6T
Other languages
Danish (da)
English (en)
Inventor
Dawn Cochrane
Jennifer Richer
Andrew A Protter
Original Assignee
Medivation Prostate Therapeutics Llc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2739153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Llc
Application granted granted Critical
Publication of DK2739153T3 publication Critical patent/DK2739153T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12846720.6T 2011-07-29 2012-07-27 TREATMENT OF BREAST CANCER DK2739153T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
DK2739153T3 true DK2739153T3 (en) 2018-12-03

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12846720.6T DK2739153T3 (en) 2011-07-29 2012-07-27 TREATMENT OF BREAST CANCER

Country Status (18)

Country Link
US (4) US9517229B2 (https=)
EP (4) EP3791724A1 (https=)
JP (2) JP6158180B2 (https=)
KR (1) KR101923250B1 (https=)
CN (1) CN103997894B (https=)
BR (1) BR112014002200A2 (https=)
CA (1) CA2843417C (https=)
CY (1) CY1121038T1 (https=)
DK (1) DK2739153T3 (https=)
EA (1) EA028452B1 (https=)
ES (1) ES2696074T3 (https=)
HU (1) HUE040524T2 (https=)
MX (1) MX359664B (https=)
PH (1) PH12014500248B1 (https=)
PL (1) PL2739153T3 (https=)
PT (1) PT2739153T (https=)
SI (1) SI2739153T1 (https=)
WO (1) WO2013066440A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843417C (en) * 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
CN105377299B (zh) * 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
JP6568093B2 (ja) * 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN107109488A (zh) 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020113088A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
SI2656842T1 (sl) * 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
EP2620432A3 (en) * 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
SG173837A1 (en) * 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
CA2843417C (en) * 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
JP6144695B2 (ja) 2011-11-30 2017-06-07 ユニバーシティー オブ ノースカロライナ アット チャペル ヒル タキサン療法を用いて乳癌を処置する方法
ES2696202T3 (es) 2012-08-23 2019-01-14 Univ Colorado Regents Método para determinar el tratamiento de cáncer de mama
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CN107109488A (zh) 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法

Also Published As

Publication number Publication date
US20190262315A1 (en) 2019-08-29
EP2739153B1 (en) 2018-08-22
BR112014002200A2 (pt) 2017-03-07
EP3610731A1 (en) 2020-02-19
CN103997894A (zh) 2014-08-20
JP6158180B2 (ja) 2017-07-05
EP3791724A1 (en) 2021-03-17
JP2017141269A (ja) 2017-08-17
KR101923250B1 (ko) 2018-11-28
CA2843417A1 (en) 2013-05-10
KR20140107174A (ko) 2014-09-04
CN103997894B (zh) 2016-08-24
EP2739153A1 (en) 2014-06-11
EA028452B1 (ru) 2017-11-30
HUE040524T2 (hu) 2019-03-28
HK1198867A1 (en) 2015-06-19
WO2013066440A9 (en) 2013-07-18
MX2014001218A (es) 2014-08-22
ES2696074T3 (es) 2019-01-14
US9517229B2 (en) 2016-12-13
CY1121038T1 (el) 2019-12-11
US10111861B2 (en) 2018-10-30
EP2739153A4 (en) 2015-03-11
PT2739153T (pt) 2018-11-28
US20210069154A1 (en) 2021-03-11
HK1201413A1 (en) 2015-09-04
MX359664B (es) 2018-10-05
WO2013066440A1 (en) 2013-05-10
CA2843417C (en) 2018-08-21
SI2739153T1 (sl) 2018-12-31
JP2014524934A (ja) 2014-09-25
PH12014500248B1 (en) 2018-08-31
PH12014500248A1 (en) 2014-03-17
US20140296312A1 (en) 2014-10-02
EA201400178A1 (ru) 2014-11-28
PL2739153T3 (pl) 2019-04-30
US20170087132A1 (en) 2017-03-30
EP3430907A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
DK2739153T3 (en) TREATMENT OF BREAST CANCER
AU2016256471B2 (en) Methods of treating cancer
CA2861056A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
HK1198867B (en) Treatment of breast cancer
CA2894153A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
WO2018195202A1 (en) Compositions and methods for the treatment of cancer
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2022238706A1 (en) Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤